These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37495439)

  • 1. Sacubitril-Valsartan in Heart Failure: The Hard Sell of Spending More to Save Later.
    Samson R; Le Jemtel TH
    Am J Cardiol; 2023 Sep; 202():237-238. PubMed ID: 37495439
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Application of Sacubitril/Valsartan in Heart Failure: Erratum.
    Am J Ther; 2022 Nov-Dec 01; 29(6):e788. PubMed ID: 36608068
    [No Abstract]   [Full Text] [Related]  

  • 3. Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure.
    Solomon SD; McMURRAY JJV
    J Card Fail; 2021 Jun; 27(6):693-695. PubMed ID: 33872760
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Application of Sacubitril/Valsartan in Heart Failure.
    Liu X; Zhong L
    Am J Ther; 2021 Apr; 28(4):e511-e513. PubMed ID: 33852477
    [No Abstract]   [Full Text] [Related]  

  • 5. Sacubitril/Valsartan in Advanced Heart Failure: Shattering the Paradigm to Focus on Real LIFE.
    Samsky MD; Sen S
    JACC Heart Fail; 2022 Jul; 10(7):457-458. PubMed ID: 35772854
    [No Abstract]   [Full Text] [Related]  

  • 6. Sacubitril/valsartan adherence… because the best is sometimes difficult to replace the good.
    Álvarez-García J
    Eur J Heart Fail; 2022 Sep; 24(9):1516-1518. PubMed ID: 35869745
    [No Abstract]   [Full Text] [Related]  

  • 7. Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
    Butt JH; McMurray JJV
    Eur J Heart Fail; 2022 Sep; 24(9):1623-1624. PubMed ID: 35919944
    [No Abstract]   [Full Text] [Related]  

  • 8. Sacubitril/valsartan: Where mechanism meets evidence-based medicine.
    Rivas García S; Álvarez-García J
    Eur J Heart Fail; 2024 Jan; 26(1):127-129. PubMed ID: 38037688
    [No Abstract]   [Full Text] [Related]  

  • 9. No Improved Patient-Oriented Outcomes With Sacubitril/Valsartan in Adults With Heart Failure and Preserved Ejection Fraction.
    Slawson DC
    Am Fam Physician; 2022 Jun; 105(6):Online. PubMed ID: 35704816
    [No Abstract]   [Full Text] [Related]  

  • 10. Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan.
    Mohebi R; Liu Y; Myhre PL; Felker GM; Prescott MF; Piña IL; Butler J; Ward JH; Solomon SD; Januzzi JL
    JACC Heart Fail; 2023 Jul; 11(7):855-858. PubMed ID: 37115131
    [No Abstract]   [Full Text] [Related]  

  • 11. The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
    Voordes GHD; Heerspink HJL; Ter Maaten JM
    Eur J Heart Fail; 2022 May; 24(5):804-806. PubMed ID: 35415946
    [No Abstract]   [Full Text] [Related]  

  • 12. Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States.
    Bhatt AS; Vaduganathan M; Lee SB; Desai RJ
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1021-1023. PubMed ID: 37227387
    [No Abstract]   [Full Text] [Related]  

  • 13. The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Crea F
    Eur Heart J; 2021 Sep; 42(36):3581-3585. PubMed ID: 34549264
    [No Abstract]   [Full Text] [Related]  

  • 14. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials.
    Cordero A; Nuñez J; Bertomeu-González V; Fácila L; Quintanilla MA; Rodríguez-Mañero M; Escribano D; Valle A; de la Espriella R; Torres-Llergo J; Bayés-Genís A; González-Juanatey JR
    Am J Ther; 2022 Sep-Oct 01; 29(5):e572-e575. PubMed ID: 36074989
    [No Abstract]   [Full Text] [Related]  

  • 15. Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
    Sinha A; Patel RB
    Eur J Heart Fail; 2023 Jan; 25(1):95-97. PubMed ID: 36445011
    [No Abstract]   [Full Text] [Related]  

  • 16. Sacubitril/Valsartan in Heart Failure and Deterioration in eGFR: Slow and Steady Win the Race.
    Jefferies JL
    JACC Heart Fail; 2024 Oct; 12(10):1704-1706. PubMed ID: 39207326
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter to the Editor regarding to 'Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control'.
    Wewer Albrechtsen NJ; Bojsen-Møller KN
    Int J Cardiol; 2022 Dec; 368():55. PubMed ID: 36037929
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In brief: Sacubitril/valsartan (Entresto) expanded indication.
    Med Lett Drugs Ther; 2021 May; 63(1623):65. PubMed ID: 33976096
    [No Abstract]   [Full Text] [Related]  

  • 20. Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction.
    Belarte-Tornero LC; Mojón D; Solé-González E; Ruiz-Bustillo S; Valdivielso-More S; Farré N
    Rev Esp Cardiol (Engl Ed); 2021 Dec; 74(12):1117-1119. PubMed ID: 34247968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.